Explore 3 court opinions on Biosimilar Drug Regulation. AI-powered plain English summaries, key holdings, and legal analysis.
3 recent cases analyzed in this topic area.
Third Circuit: Biosimilar Renflexis Does Not Infringe Remicade Patents
Johnson & Johnson v. Samsung Bioepis Co Ltd, decided by Third Circuit on April 14, 2026, resulted in a defendant win outcome. The Third Circuit affirmed the District Court's grant of summary judgment ...
CA3 Affirms Enbrel Patent Infringement, Reverses Willfulness Finding
Amgen Inc v. Celltrion USA Inc, decided by Third Circuit on June 5, 2025, resulted in a mixed outcome. The Third Circuit affirmed the District Court's finding of infringement of Amgen's patents for it...
Federal Circuit Affirms Biosimilar Infringement Finding Against Mylan
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., decided by Federal Circuit on March 14, 2025, resulted in a plaintiff win outcome. The core dispute centered on whether Mylan's proposed ...